Table 2 Multivariate analysis of clinicopathological characteristics of all cases for disease-free survival and overall survival.

From: The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study

 

All patients

Stage IA patients

Disease-free survival

Overall survival

Disease-free survival

Overall survival

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

Groups

 

0.997

 

0.009

 

0.967

 

0.196

    EC without AM

Reference

—

Reference

—

Reference

—

Reference

—

    EC-A

1.029 (0.439–2.411)

0.947

5.033 (1.803–14.048)

0.002

0.869 (0.297–2.544)

0.797

3.066 (0.909–10.343)

0.071

    EC-AIA

0.000 (0.000-N/A)

0.971

0.000 (0.000-N/A)

0.987

0.000 (0.000-N/A)

0.987

0.000 (0.000-N/A)

0.990

Age

1.021 (0.989–1.054)

0.208

1.003 (0.957–1.051)

0.902

1.016 (0.982–1.051)

0.360

1.001 (0.954–1.051)

0.967

Gravidity

1.016 (0.681–1.516)

0.938

0.816 (0.478–1.393)

0.456

0.941 (0.620–1.431)

0.777

0.798 (0.451–1.414)

0.440

Parity

0.992 (0.759–1.295)

0.951

1.277 (0.899–1.812)

0.172

1.082 (0.815–1.437)

0.587

1.288 (0.886–1.870)

0.184

Co-existing endometriosis

    No

Reference

—

Reference

—

Reference

—

Reference

—

    Yes

0.964 (0.217–4.289)

0.962

0.000 (0.000-N/A)

0.978

0.000 (0.000-N/A)

0.980

0.000 (0.000-N/A)

0.984

Surgical route

    Laparoscopy

Reference

—

Reference

—

Reference

—

Reference

—

    Laparotomy

0.684 (0.360–1.300)

0.247

0.251 (0.100–0.632)

0.003

0.443 (0.222–0.884)

0.021

0.214 (0.079–0.577)

0.002

Differential of endometrioid EC

 

0.031

 

0.438

 

0.046

 

0.805

    Grade 1

Reference

—

Reference

—

Reference

—

Reference

—

    Grade 2

1.675 (0.829–3.386)

0.151

0.899 (0.290–2.785)

0.853

2.164 (1.018–4.601)

0.045

1.211 (0.398–3.682)

0.736

    Grade 3

3.173 (1.342–7.501)

0.009

2.048 (0.560–7.485)

0.279

3.083 (1.154–8.235)

0.025

1.694 (0.345–8.312)

0.516

FIGO stages

    Stage I-II, n (%)

Reference

—

Reference

—

—

—

—

—

    Stage III-IV, n (%)

6.115 (1.897–19.712)

0.002

0.831 (0.138–5.000)

0.840

—

—

—

—

Maximum diameter of the tumor

1.009 (0.995–1.023)

0.206

1.009 (0.992–1.026)

0.286

1.003 (0.987–1.019)

0.696

1.009 (0.992–1.027)

0.312

LVSI

    Negative

Reference

—

Reference

—

Reference

—

Reference

—

    Positive

1.753 (0.778–3.950)

0.176

1.450 (0.366–5.750)

0.597

2.235 (0.874–5.717)

0.093

2.030 (0.408–10.105)

0.387

Postoperative adjuvant therapy

    No

Reference

—

Reference

—

Reference

—

Reference

—

    Yes

3.547 (1.640–7.672)

0.001

2.749 (0.820–9.214)

0.101

3.075 (1.367–6.919)

0.007

1.707 (0.422–6.908)

0.453

  1. Abbreviations: AM, adenomyosis; EC, endometrial cancer; EEC-AIA, endometrial endometrioid carcinoma arising in adenomyosis; FIGO, Federation International of Gynecology and Obstetrics; HR, hazard ratios; 95% CI, 95% confidence interval; LVSI, lymph-vascular space invasion; N/A, not available.
Back to article page